💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Cytarabine

CHEMBL803 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
243.2 g/mol
LogP
-2.1
Phase
4

A pyrimidine nucleoside analogue that interferes with DNA synthesis by inhibiting DNA polymerase, used primarily to treat acute myeloid leukemia and other hematologic malignancies. It is often given in high-dose regimens and can cause cerebellar toxicity.

الوزن الجزيئي

243,2200 g/mol

LogP

-2,10

TPSA

129,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Pain Management Non-Small Cell Lung Cancer Melanoma Systemic Lupus Erythematosus Multiple Sclerosis Lymphoma Breast Cancer Chronic Pain Colorectal Cancer Leukemia

آلية العمل

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1

                

                

                
                

                    
InChI

                    
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H13N3O5

                    

                    
                    

                        
HBD / HBA

                        
4 / 5

                    

                    
                    

                        
الروابط القابلة للدوران

                        
2

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
A pyrimidine nucleoside analogue that interferes with DNA synthesis by inhibiting DNA polymerase, used primarily to treat acute myeloid leukemia and other hematologic malignancies. It is often given in high-dose regimens and can cause cerebellar toxicity.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Cytarabine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL803.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6253.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.